Kauffman Michael Form 4 August 08, 2018

## FORM 4

### **OMB APPROVAL**

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16. Form 4 or

January 31, Expires: 2005

Estimated average burden hours per

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

response... 0.5

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person ** Kauffman Michael			2. Issuer Name <b>and</b> Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer		
			Karyopharm Therapeutics Inc. [KPTI]	(Check all applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	_X_ Director 10% Owner _X_ Officer (give title Other (specify		
C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS			08/07/2018	below) below) Chief Executive Officer		

**AVENUE** 

(Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

**NEWTON, MA 02459** 

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit onor Dispos (Instr. 3, 4	ed of	` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	08/07/2018		M(1)	12,500	A	\$ 0.033	726,010	I	By Spouse		
Common Stock	08/07/2018		S(1)	12,500	D	\$ 18.0445 (2)	713,510	I	By Spouse		
Common Stock							512,143	D			
Common Stock							47,309	I	By GRAT (3)		

By Common 47,309 I Spouse's Stock GRAT (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.033	08/07/2018		M <u>(1)</u>	12,500	<u>(5)</u>	10/21/2020	Common Stock	12,500

## **Reporting Owners**

Relationships Reporting Owner Name / Address Other Director 10% Owner Officer

Kauffman Michael

C/O KARYOPHARM THERAPEUTICS INC. Chief Executive Officer X **85 WELLS AVENUE** 

NEWTON, MA 02459 **Signatures** 

/s/ Christopher B. Primiano, Attorney-in-Fact for Michael G. Kauffman

08/08/2018 Date

\*\*Signature of Reporting Person

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

Reporting Owners 2

#### Edgar Filing: Kauffman Michael - Form 4

- Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$17.60 to \$18.85,
- (2) inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (3) These shares are held by the Michael G. Kauffman 2016 Qualified Annuity Interest Trust.
- (4) These shares are held by the Sharon Shacham 2016 Qualified Annuity Interest Trust.
- (5) This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.